Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme and Schering have reported results from an end-stage trial that suggest the drug Campath is superior to the chemotherapy chlorambucil in patients with B-cell chronic lymphocytic leukemia.
Subscribe to our email newsletter
The study met its primary endpoint by demonstrating superior progression free survival in patients with B-cell chronic lymphocytic leukemia (B-CLL) treated with Campath versus chlorambucil. Campath reduced the risk of disease progression or death by 42%.
The secondary endpoint analyses showed that patients who received Campath given for a median of nearly twelve weeks exhibited significantly higher overall and complete response rates, with a manageable safety profile, compared with those patients who were treated with chlorambucil for a median of twenty-four weeks. The data showed a nearly 30% greater overall response rate among patients treated with Campath compared to chlorambucil.
“The high response rates, longer progression-free survival, and extended treatment-free intervals in these patients, in addition to other clinical data, support that Campath is one of the most active single agents in CLL and confirm its place as a key component of any future studies in combination or consolidation therapy.” stated lead investigator Peter Hillmen of the Leeds General Infirmary, UK.